<DOC>
	<DOC>NCT01092611</DOC>
	<brief_summary>The purpose of this long-term follow-up study is to assess the long-term health status of HIV-infected subjects who previously participated in GSK-sponsored trials evaluating the investigational HIV vaccine 732462. This study will provide additional data concerning the long-term benefits/risks associated with vaccination. No vaccine will be administered during the study period. Vaccines were administered during the primary studies.</brief_summary>
	<brief_title>Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine</brief_title>
	<detailed_description>General information on the health of the subject and persistence of the cellular and humoral immune responses to study vaccination will be evaluated.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subjects must satisfy ALL the following criteria at study entry: HIVinfected subject. Previous participation in a study evaluating GSK HIV vaccine 732462. Written informed consent obtained from the subject. The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study: â€¢ Subjects who did not receive a complete vaccination course in previous studies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>HIV-infected subjects</keyword>
	<keyword>long-term follow-up study</keyword>
	<keyword>HIV therapeutic vaccine</keyword>
</DOC>